CN112618718A - Substance for improving killing power of immune cells and preparation and application thereof - Google Patents

Substance for improving killing power of immune cells and preparation and application thereof Download PDF

Info

Publication number
CN112618718A
CN112618718A CN202011590045.0A CN202011590045A CN112618718A CN 112618718 A CN112618718 A CN 112618718A CN 202011590045 A CN202011590045 A CN 202011590045A CN 112618718 A CN112618718 A CN 112618718A
Authority
CN
China
Prior art keywords
acid
substance
immune cells
improving
killing power
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011590045.0A
Other languages
Chinese (zh)
Inventor
陈致慜
殷苗苗
刘会云
王珍
王梦蕾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Handan Pharmaceutical Co ltd
Original Assignee
Handan Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Handan Pharmaceutical Co ltd filed Critical Handan Pharmaceutical Co ltd
Priority to CN202011590045.0A priority Critical patent/CN112618718A/en
Publication of CN112618718A publication Critical patent/CN112618718A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a substance for improving immunocyte lethality and a preparation and application thereof, the substance for improving immunocyte lethality is berberine, benzoyl oxidized paeoniflorin, methyl ophiopogon root brass A, tetrahydroberberine, kaempferol 3-O-morubide, corydalis pulchella, bicuculline, clidinine A, harpagide, dendrobine, berberine hydrochloride, coptisine, norisoboldine, ginsenoside Rg3 and isochlorogenic acid A, L-arginine, 3-O ferulic acid acyl quininic acid, red ganoderma ketone, atractyloside A, ginsenoside Rh3, cholic acid, oleuropein, paliperidone A, paliperidone B, trans-ferulate p-hydroxyphenylethanol, peonie dione, pseudoginsenoside RT1, anisic lactone, p-hydroxybenzoic acid, porcinic acid, epoxy alisol and one or more of alpha-cyperone. In the invention, immune related genes such as CD46, MUC16, TGF-beta and the like and GAST and SS18 are selected from genes with remarkably changed expression levels in transcriptome analysis data and are used as target genes for direct or indirect regulation.

Description

Substance for improving killing power of immune cells and preparation and application thereof
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a substance for improving killing power of immune cells, and a preparation and application thereof.
Background
Chronic Atrophic Gastritis (CAG) is a chronic disease of the digestive system characterized by atrophy of gastric mucosal epithelium and glandular tissue, a decrease in the number of mucosal cells, a thinning of the gastric mucosa, a thickening of the mucosal basal layer, or with pyloric and intestinal glandular metaplasia, or with atypical hyperplasia. China is a high-incidence area of gastric cancer, and most of gastric cancer occurrence processes follow a gastric cancer occurrence mode proposed by a corea cascade reaction: normal gastric mucosa-superficial gastritis-atrophic gastritis-small intestine type intestinal metaplasia-large intestine type intestinal metaplasia-dysplasia (moderate and severe) -gastric cancer, wherein the central part of the lesion axis where the CAG is located has important bearing function for the development and prognosis of diseases. Therefore, the research on the CAG treatment measures has important clinical significance for preventing and treating the gastric cancer. The mucous epithelial cells belong to a renewal cell group, the proliferation-apoptosis dynamic balance maintains the relative constant number of the cell group in the physiological state, the integrity and the normal function of the gastric mucosa are maintained, and the dynamic balance result determines the normal state or the pathological change of the gastric tissue. Atrophic gastritis with low immune function is a common subgroup in clinic and is manifested by low cellular immunity and low humoral immunity. Immunoglobulin levels such as IgG, IgA and IgM in serum of a patient with chronic atrophic gastritis and low immune function are obviously reduced, expressions such as pepsinogen I, II (PGI and PGII) and Gastrin (GAS) are obviously reduced, somatostatin (SS) is obviously increased, and the level of an immune factor is obviously reduced.
The Moluo Dan is a pure Chinese medicinal preparation consisting of 18 medicinal materials of lily, tuckahoe, figwort root, combined spicebush root, oriental waterplantain rhizome, dwarf lilyturf tuber, Chinese angelica, largehead atractylodes rhizome, virgate wormwood herb, white paeony root, dendrobium, irkutsk anemone rhizome, Szechuan lovage rhizome, pseudo-ginseng, garden burnet root, corydalis tuber, cattail pollen and chicken's gizzard-membrane, has the functions of harmonizing the stomach and strengthening the spleen, freeing the collateral vessels and relieving pain, strengthening. In recent years, the research on the treatment of chronic atrophic gastritis by morrhodin has been advanced. The Moluodan is selected as a first recommended medicine for treating chronic gastritis and chronic atrophic gastritis by the Chinese Chronic gastritis consensus opinion (2017) formulated by the digestive diseases society of the Chinese medical society and the Chronic gastritis expert diagnosis and treatment consensus opinion (2017) published by the Chinese medical society. The combined use of the above medicines can play roles in harmonizing stomach, lowering adverse qi, strengthening spleen, relieving flatulence, dredging collaterals and relieving pain, and has a remarkable regulation effect on CAG spleen and stomach weakness and stomach disorder. Moluodan can obviously reduce the expression of EGF and EGFR of CAG patients. However, studies on core active ingredients of morganan, which can enhance the immune function of atrophic gastritis and the action of immune regulator, have been lacking in the past.
Disclosure of Invention
The invention carries out transcriptome analysis on gastric epithelial cells treated by the Moluodan, and the analysis result shows that the Moluodan mainly influences the biological processes of cell cycle, proliferation, apoptosis, DNA damage repair and the like in the cells. The literature reports that CD46 functions as a type I membrane-localized glycoprotein as a receptor for a variety of human pathogenic bacterial proteins in all nucleated cells. CD46 can regulate cell proliferation process, significantly improve T cell immune activity, and stimulate natural cellular immunity. MUC16 encodes tumor associated antigen CA125, and its transcription level is down-regulated, and its tumor occurrence probability is obviously down-regulated. In addition, the study shows that MUC16 can be used as downstream regulatory genes of cytokines IL-1 beta, IL-6, TNF-alpha and the like to participate in immune response. TGF-beta acts as an important promoter of immune homeostasis and immune tolerance, inhibits the expansion and function of various components of the immune system, and inhibits the transduction of TGF-beta signals, which can significantly affect the immune system and inflammatory response.
Therefore, in the invention, immune related genes such as CD46, MUC16, TGF-beta and the like and GAST and SS18 are selected from genes with remarkably changed expression levels in transcriptome analysis data as a morrhodin direct or indirect regulation target gene.
The first object of the present invention is to provide a substance which enhances the killing ability of immune cells; the second purpose is to provide a preparation of the substance for improving the lethality of the immune cells; the third purpose is to provide the application of the substance for improving the lethality of the immune cells.
The first purpose of the invention is realized by that the substance for improving the killing power of the immune cells is one or more of berberine, benzoyl oxidized paeoniflorin, methyl ophiopogon root high brass A, tetrahydroberberine, kaempferol 3-O-morubide, corydaline, bicuculline, camptoside A, harpagoside, dendrobine, berberine hydrochloride, norisoboldine, ginsenoside Rg3, isochlorogenic acid A, L-arginine, 3-O ferulic acid acyl quinic acid, erythronolide, atractyloside A, ginsenoside Rh3, cholic acid, oleuropexin, palisenoside A, paliperidone B, p-hydroxyphenylethanol trans-ferulate, peonie, pseudoginsenoside RT1, anisic lactone, p-hydroxybenzoic acid, performic acid, epoxy alisol and alpha-cyperone.
The second purpose of the invention is realized by adding pharmaceutically acceptable auxiliary materials into the substance for improving the killing power of the immune cells to prepare tablets, capsules, pills, injection, sustained release agents, controlled release agents, powder or oral liquid preparations.
The third purpose of the invention is realized by the application of the substance for improving the lethality of the immune cells in the preparation of the medicine for treating the chronic atrophic gastritis.
The invention further defines the action target of the effective substances in the morgan by researching high-throughput transcript analysis (RNAseq) through morgan cytology experiments, and finally verifies the effective substances for treating the chronic atrophic gastritis by regulating the immunologic function in the morgan through a fluorescence quantification (qRT-PCR) method. The work performed by the present inventors includes:
1) identification of natural medicine components contained in Moluodan
The present inventors identified effective natural drug components contained in molhodan by using a method of metabonomic analysis. The analysis result shows that the moluodan contains 220 compounds, which is consistent with the result of literature mining.
2) Enrichment analysis of biological function of regulating and controlling drug components in molluo
The morrhodin was applied to the gastric epithelial cell culture medium, and the cells were harvested 24h after treatment and transcriptome analysis. Through enrichment analysis, the biological functions mainly influenced by the molsidan and the functions of the regulated target genes are distinguished. Through analysis of related regulatory factors reported in the literature, the medicine components in the fingerprint of the morganan are further identified, and the effective components for regulating and controlling the hypoimmunity in the morganan are further accurate.
3) Effective substance for regulating and controlling immune function in molodan through fluorescent quantitative verification
And (4) screening out target genes related to the immune function regulation in the molhodan by analyzing the analysis result of the transcriptome. And (3) carrying out quantitative detection on the cell transcript processed by the predicted effective component in each Moluo rhodamine by designing specific primers corresponding to each target gene. In the experiment, various predicted effective components in the molhoduon are subjected to apoptosis detection experiments and literature mining to obtain the appropriate treatment concentration of each predicted component. It is predicted that each effective fraction was applied to SGC-7901 cell culture medium cultured in 6-well plates after being dissolved in DMSO, and DMSO-treated cells were used as a negative control group. SGC-7901 cells were harvested 24 hours after drug treatment and RNA extraction was performed. Then, the nucleic acid after reverse transcription is subjected to fluorescent quantitative detection by using a qRT-PCR method. The qRT-PCR quantitative detection target gene is derived from an RNAseq analysis result, and the genes respectively participate in biological processes such as immune reaction, inflammatory reaction, cell proliferation, apoptosis and the like. In this experiment, changes in gene transcripts such as CD46, MUC16 and TGF-. beta.were used as marker genes for immune response regulation. Altered levels of CDK1, CDK6, and SMAD6 gene expression were used as reference genes for cell proliferation. Changes in CASP9 and TP53 transcript levels were detected as reference standards for apoptosis. Gastrins GAST and SS18 are used as effective components of Moluodan to improve and regulate the detection target genes of chronic atrophic gastritis.
Drawings
FIG. 1 is a schematic representation of the increased expression of CD46 by a portion of an agent that increases the lethality of immune cells according to the present invention;
FIG. 2 is a schematic representation of the inhibition of MUC16 expression by a moiety that enhances the killing power of immune cells according to the invention;
FIG. 3 is a schematic representation of the partial agents of the invention that increase killing of immune cells inhibiting the expression of TGF- β;
FIG. 4 is a schematic representation of the partial agents that enhance killing of immune cells of the present invention increasing GAST expression;
FIG. 5 is a schematic representation of the increased expression of GAST by another agent that increases the lethality of immune cells of the present invention;
FIG. 6 is a schematic representation of the increased expression of GAST by a third agent that increases killing of immune cells according to the invention;
FIG. 7 is a schematic representation of the partial agents of the present invention that enhance the lethality of immune cells inhibiting the expression of SS 18;
FIG. 8 is a schematic representation of the inhibition of SS18 expression by another agent that enhances the lethality of immune cells according to the present invention.
Detailed Description
The present invention is further illustrated by the following examples and the accompanying drawings, but the present invention is not limited thereto in any way, and any modifications or alterations based on the teaching of the present invention are within the scope of the present invention.
The substance for improving the killing power of the immune cells is one or more of berberine, benzoyl oxidized paeoniflorin, methylpriope muscari high brass A, tetrahydroberberine, kaempferol 3-O-morubide, corydaline, bicuculline, senecin A, harpagide, dendrobine, coptisine hydrochloride, coptisine, norisoboldine, ginsenoside Rg3, isochlorogenic acid A, L-arginine, 3-O ferulic acid acyl quinic acid, erythronolide, atractyloside A, ginsenoside Rh3, cholic acid, oleuropein, balisonn A, balisonn B, trans-ferulate p-hydroxyphenylethanol, paeonedione, pseudoginsenoside RT1, anisic lactone, p-hydroxybenzoic acid, performic acid, epoxy alisol and alpha-cyperone.
One or more of berberine, benzoyloxypaeoniflorin, methylpriope muscari A, tetrahydroberberine, kaempferol 3-O-mulberry bisoside, corydaline, bicuculline and scirpenin A is/are expressed by improving CD46 to improve the killing power of immune cells.
One or more of berberine, benzoyloxypaeoniflorin, methylpriope muscari A, tetrahydroberberine, kaempferol 3-O-sambucoside, corydaline, bicuculline and scirpenin A is/are used for improving the killing power of immune cells by inhibiting the expression of MUC 16.
One or more of berberine, benzoyloxypaeoniflorin, methylpriope muscari A, tetrahydroberberine, kaempferol 3-O-mulberry bisoside, corydaline, bicuculline and scirpenin A is/are used for improving the killing power of immune cells by inhibiting the expression of TGF-beta.
One or more of harpagide, dendrobine, coptisine hydrochloride, coptisine, norisoboldine, ginsenoside Rg3, isochlorogenic acid A, L-arginine, 3-O ferulic acid acyl quinic acid, lucidone, atractyloside A, ginsenoside Rh3, cholic acid, oleuropein, palisenoside A, paliperidone B, p-hydroxyphenylethanol trans-ferulate, peony dione, pseudoginsenoside RT1, anisic lactone, p-hydroxybenzoic acid, poriferin, epoxy alisol and alpha-cyperone is/are used for improving the killing power of immune cells by improving the expression of GAST.
One or more of harpagide, dendrobine, coptisine hydrochloride, coptisine, norisoboldine, ginsenoside Rg3, isochlorogenic acid A, L-arginine, 3-O ferulic acid acyl quinic acid, lucidone, atractyloside A, ginsenoside Rh3, cholic acid, oleuropein, palisenoside A, paliperidone B, p-hydroxyphenylethanol trans-ferulate, peony dione, pseudoginsenoside RT1, anetholide, p-hydroxybenzoic acid, poriferin, epoxy alisol and alpha-cyperone is/are used for improving the killing power of immune cells by inhibiting the expression of SS 18.
The preparation of the substance for improving the killing power of the immune cells is a tablet, a capsule, a pill, an injection, a sustained release agent, a controlled release agent, a powder or an oral liquid preparation prepared by adding pharmaceutically acceptable auxiliary materials into the substance for improving the killing power of the immune cells.
The application of the substance for improving the killing power of the immune cells is the application of the substance for improving the killing power of the immune cells in preparing a medicine for treating chronic atrophic gastritis.
The application of the substance for improving the killing power of the immune cells is the application of the substance for improving the killing power of the immune cells in preparing a medicament for treating atrophic gastritis accompanied with low immune function.
The application of the substance for improving the killing power of the immune cells is the application of the substance for improving the killing power of the immune cells in preparing the medicine for improving the immunity of the atrophic gastritis.
The invention is further illustrated by the following specific examples:
example 1
Moluodan for treating atrophic gastritis with immunologic hypofunction
Chronic atrophic gastritis is usually accompanied by hypoimmunity, and is closely related to signal pathways such as immune metabolism, apoptosis, proliferation, and DNA damage repair. The method establishes the fingerprint of the molhoduo through metabonomics analysis. And further combining literature information mining to preliminarily screen candidate effective components in the molhoduo. Then, the cytological and molecular experimental verification is carried out to identify effective medicinal components for treating atrophic gastritis with low immunologic function in the molhodan, and the steps are as follows:
1. establishment of Moluodan fingerprint
In order to identify and identify the components which are used for effectively treating atrophic gastritis and have low immune function in the molhoduo, the inventor carries out metabonomics analysis on the molhoduo and successfully identifies 220 compound components through database comparison. The partial compound components are shown in table 1.
TABLE 1 Moluodan Compound component (part)
Number of medicine Name of English Name of Chinese
1 Berberine Berberine (Berberine)
2 Benzoyloxypaeoniflorin Benzoyl oxidized paeoniflorin
3 Methylophiopogonone A Radix Ophiopogonis methyl high brass A
4 Canadin（Tetrahydroberberine） Tetrahydroberberine
5 Leucoside（Kaempferol 3-O-sambubioside） Kaempferol 3-O-mulberry budesonide
6 Cheilanthifoline Corydaline leaf
7 Bucuculline Bihuoxiling alkali
8 Sibirioside A All-grass of Clematis Spinosa
9 Harpagide Harpagoside
10 Dendrobine Dendrobine
11 Coptisine hydrochloride Coptisine hydrochloride
12 Coptisine Coptisine
13 Norisoboldine Norisoboldine
14 Ginsenoside Rg3 Ginsenoside Rg3
15 3,5-Dicaffeoyl quinic acid Isochlorogenic acid A
16 L-Arginine L-arginine
17 3-O-Feruloylquinic acid 3-O Ferulic acid acyl quininic acid
18 Lucidone Ganoderma lucidum ketone
19 Atractyloside A Atractyloside A
20 Ginsenoside Rh3 Ginsenoside Rh3
21 Cholan-24-oic acid Cholic acid
22 Oleuropein Oleuropein
23 Parishin A Balisin A
24 Parishin B Balisin B
25 p-Hydroxyphenethyl trans-ferulate Para hydroxybenzene ethanol trans ferulic acid ester
26 Palbinone Paeonedione
27 Pseudo-ginsenoside RT1 Pseudoginsenoside RT1
28 Pimpinellin Anise lactone
29 4-Hydroxybenzoic acid P-hydroxybenzoic acid
30 Eburicoic acid Tooth hole acid
31 Alismoxide Epoxy alisol
32 α-Cyperone Alpha-cyperone
33 Ligustilide Ligustilide
34 (+)-12-Hydroxy-alpha-cyperone (+) -12 hydroxy alpha-cyperone
35 Artabsin Artemisia lactone (Artemisia absinthin)
36 o-Tyrosine Ortho-tyrosine
37 Methylophiopogonone A Megestrol A
38 Cinnamic acid Cinnamic acid
39 Alisol P Alisol P
40 Alisol B 23-acetate 23-acetyl alisol B
41 Ophiopogonanone A Ophiopogon japonicus (L.) Ker-Gawl
42 α-Cyperone Alpha-cyperone
43 Ochotensine Orocaverine
44 Orientalol
45 Ophiopogonone C Ophiopogonone C
46 Alismoxide Epoxy alisol
47 Alpha-Linolenic acid Linolenic acid
48 Ruscogenin Rusco sapogenin
49 Humulene Lupulin
50 Ophiopogonanone C Radix Ophiopogonis flavanone C
2. Screening of Moluodan effective component regulation and control target gene
To explore the specific molecular regulation mechanism of morrhodin in the treatment of atrophic gastritis, the inventors performed transcriptome analysis on morrhodin-treated gastric epithelial cells. Analysis results show that the morrhodanes mainly influence the biological processes of cell cycle, proliferation, apoptosis, differentiation, DNA damage repair and the like in cells. The literature reports that CD46 functions as a type I membrane-localized glycoprotein as a receptor for a variety of human pathogenic bacterial proteins in all nucleated cells. CD46 can regulate cell proliferation process, significantly improve T cell immune activity, and stimulate natural cellular immunity. CDK1 and CDK6, as important components of the CDK family, play important roles in the cell proliferation process. CDK1 can synergistically act with cyclin B to promote cells to enter the meiotic stage, and research shows that the rising expression level of CDK1 is closely related to cancer cell proliferation or poor prognosis of cancer. Furthermore, the literature reports that CDK6 is overexpressed in breast cancer cells, the expression level of which is closely linked to cell proliferation. MUC16 encodes tumor associated antigen CA125, and its transcription level is down-regulated, and its tumor occurrence probability is obviously down-regulated. In addition, the study shows that MUC16 can be used as downstream regulatory genes of cytokines IL-1 beta, IL-6, TNF-alpha and the like to participate in immune response. TP53 is a transcription repressing factor, and when slight damage occurs to cellular DNA, TP53 initiates a number of downstream genes, including CDK gene regulation, cell cycle arrest, and initiation of DNA damage repair. However, in the case of severe damage to cellular DNA, TP53 will induce the expression of apoptotic factors, indicating that the cells enter programmed death. The study shows that the SMAD6 as an inhibitory transcription factor can regulate the cell proliferation process through a BMP signal channel and further participate in the inflammatory response. In mesenchymal progenitor cells, TRAF3 may positively regulate the cellular differentiation process. TGF-beta acts as an important promoter of immune homeostasis and immune tolerance, inhibits the expansion and function of various components of the immune system, and inhibits the transduction of TGF-beta signals, which can significantly affect the immune system and inflammatory response.
Therefore, the invention selects genes related to apoptosis, proliferation and immunity such as CD46, MUC16, TGF-beta, GAST, SS18 and the like from genes with remarkably changed expression quantity in transcriptome analysis data as morrhodin direct or indirect regulation target genes.
3. Screening of functional effective components of Moluodan for treating atrophic gastritis and hypoimmunity
Combining the reports about the drug effect of natural compounds of the drugs in the literature and comprehensively considering the problems of drug purchase, application and the like. The inventors screened 49 compounds from the fingerprint chromatogram library of Morgan and conducted cytological experiments (Table 2). Various compound cytological experiments were reported with concentration references or established with IC50 assays.
TABLE 2 latent effective component of Moluodan
Name of English Name of Chinese Purchase company
Berberine Berberine (Berberine) JIANGSU YONGJIAN PHARMACEUTICAL TECHNOLOGY Co.,Ltd.
Benzoyloxypaeoniflorin Benzoyl oxidized paeoniflorin Tianjin Vientiane Hengyuan Technology Co.,Ltd.
Methylophiopogonone A Radix Ophiopogonis methyl high brass A Tianjin Vientiane Hengyuan Technology Co.,Ltd.
Canadin（Tetrahydroberberine） Tetrahydroberberine Chengdu Desite Biotechnology Ltd
Leucoside（Kaempferol 3-O-sambubioside） Kaempferol 3-O-mulberry budesonide Shanghai coconut accurate Biotechnology Co., Ltd
Cheilanthifoline Corydaline leaf Chengdu Desite Biotechnology Ltd
Bucuculline Bihuoxiling alkali SHANGHAI STANDARD TECHNOLOGY Co.,Ltd.
Sibirioside A All-grass of Clematis Spinosa SHANGHAI YUANYE BIOTECHNOLOGY Co.,Ltd.
Harpagide Harpagoside China Institute for food and drug control
Dendrobine Dendrobine China Institute for food and drug control
Coptisine hydrochloride Coptisine hydrochloride JIANGSU YONGJIAN PHARMACEUTICAL TECHNOLOGY Co.,Ltd.
Coptisine Coptisine phenchem
Norisoboldine Norisoboldine China Institute for food and drug control
Ginsenoside Rg3 Ginsenoside Rg3 China Institute for food and drug control
3,5-Dicaffeoyl quinic acid Isochlorogenic acid A Chengdu Desite Biotechnology Ltd
L-Arginine L-arginine Chengdu Desite Biotechnology Ltd
3-O-Feruloylquinic acid 3-O Ferulic acid acyl quininic acid Tianjin Vientiane Hengyuan Technology Co.,Ltd.
Lucidone Ganoderma lucidum ketone Tianjin Vientiane Hengyuan Technology Co.,Ltd.
Atractyloside A Atractyloside A Guangzhou city of Chinese medicineCloud Biotechnology Ltd
Ginsenoside Rh3 Ginsenoside Rh3 Wuhantian ChemFaces
Cholan-24-oic acid Cholic acid Chengdu Desite Biotechnology Ltd
Oleuropein Oleuropein Qiyun Biotech, Guangzhou City
Parishin A Balisin A SHANGHAI STANDARD TECHNOLOGY Co.,Ltd.
Parishin B Balisin B SHANGHAI STANDARD TECHNOLOGY Co.,Ltd.
p-Hydroxyphenethyl trans-ferulate Para hydroxybenzene ethanol trans ferulic acid ester Tianjin Vientiane Hengyuan Technology Co.,Ltd.
Palbinone Paeonedione Tianjin Vientiane Hengyuan Technology Co.,Ltd.
Pseudo-ginsenoside RT1 Pseudoginsenoside RT1 Chengdu Desite Biotechnology Ltd
Pimpinellin Anise lactone Chengdu Desite Biotechnology Ltd
4-Hydroxybenzoic acid P-hydroxybenzoic acid Chengdu Desite Biotechnology Ltd
Eburicoic acid Tooth hole acid Qiyun Biotech, Guangzhou City
Alismoxide Epoxy alisol Guangzhou city Qiyun biotechnology limited public
α-Cyperone Alpha-cyperone China Institute for food and drug control
4. Identification of Moluodan substance for improving immunologic function of atrophic gastritis
In this experiment, the SGC-7901 cell line (deposited in the ATCC cell bank by cryopreservation in this laboratory) was used as a drug treatment target. The cell has the characteristics of rapid propagation, easy culture and the like. SGC-7901 cells were seeded on 6-well plates (50 w cells per well) and cultured using DMEM (10% FBS) medium to total adherence. The Moluodan candidate active ingredient is dissolved by DMSO, and is applied to SGC-7901 cell culture solution respectively, and treated cells are collected after incubation for 24 h. Extracting RNA, performing reverse transcription, and performing qRT-PCR detection by using a gene specific primer to be detected.
Experimental results show that the morganan contains various substances and has a regulating effect on signal molecules related to immune functions. For example, berberine (berberine), benzoyloxyponiflorin, methylpriope muscari A, tetrahydroberberine, kaempferol 3-O-morubide, corydaline, bicuculline and scirpenin A can remarkably improve the expression of CD46 (figure 1) and can remarkably inhibit the expression of MUC16 (figure 2) and TGF-beta (figure 3). Therefore, the components contained in the molochan can improve the immunocompetence in the aspects of improving the killing power of immune cells, regulating cell proliferation, relieving immune suppression and the like, and treat atrophic gastritis.
To further verify the effect of morrhodane in the treatment of atrophic gastritis, the inventors quantitatively detected the target genes GAST and SS18 which mark the physiological state of gastric cells. The results show that the expression of GAST can be obviously improved by harpagide, dendrobine, coptisine hydrochloride, coptisine, norisoboldine, ginsenoside Rg3, isochlorogenic acid, AL-arginine, 3-O ferulic acid acyl quinic acid, lucidone, atractyloside A, ginsenoside Rh3, cholic acid, oleuropein, barcinoside A, barcinoside B, trans-ferulate p-hydroxyphenylethanol, peony dione, pseudoginsenoside RT1, anisic lactone, p-hydroxybenzoic acid, performic acid, epoxy alisol and alpha-cyperone (figure 4, figure 5 and figure 6). Meanwhile, the above components can also obviously inhibit the expression of SS18 (FIG. 7, FIG. 8).

Claims (10)

1. A substance for enhancing the lethality of immune cells, characterized in that, the substance for improving the killing power of the immune cells is one or more of berberine, benzoyl oxidized paeoniflorin, methylpriope muscari A, tetrahydroberberine, kaempferol 3-O-morubioside, corydaline, bicuculline, senecin A, harpagide, dendrobine, coptisine hydrochloride, coptisine, norisoboldine, ginsenoside Rg3, isochlorogenic acid A, L-arginine, 3-O ferulic acid acyl quinic acid, erythronolide, atractyloside A, ginsenoside Rh3, cholic acid, oleuropein, barcinoside A, barcinoside B, trans-ferulate p-hydroxyphenylethanol, peonie dione, pseudoginsenoside RT1, anisic lactone, p-hydroxybenzoic acid, poriferin, epoxy alisol and alpha-cyperolone.
2. The substance of claim 1, wherein the one or more of berberine, benzoyloxypaeoniflorin, methylpriope muscovine A, tetrahydroberberine, kaempferol 3-O-sambucoside, corydaline, bicuculline and scirpenin A is/are expressed by increasing CD46 to increase the killing power of the immune cells.
3. The substance of claim 1, wherein one or more of berberine, benzoyloxypaeoniflorin, methylpriope muscovine A, tetrahydroberberine, kaempferol 3-O-sambucoside, corydaline, bicuculline and clitocide A is/are expressed by inhibiting MUC16 to increase the killing power of the immune cells.
4. The substance of claim 1, wherein the one or more of berberine, benzoyloxypaeoniflorin, methylpriope muscovine A, tetrahydroberberine, kaempferol 3-O-sambucoside, corydaline, bicuculline and scirpenin A is/are expressed by inhibiting TGF- β to increase the killing power of the immune cells.
5. The substance for improving killing power of immunocytes according to claim 1, wherein one or more of harpagide, dendrobine, coptisine hydrochloride, coptisine, norisoboldine, ginsenoside Rg3, isochlorogenic acid A, L-arginine, 3-O feruloylquinic acid, lucidone, atractyloside A, ginsenoside Rh3, cholic acid, oleuropein, paliperidone A, paliperidone B, trans-ferulate p-hydroxyphenylethanol, peonie, pseudoginsenoside RT1, anisic lactone, p-hydroxybenzoic acid, poriferic acid, oxyphyllene oxide and alpha-cyperone is used for improving killing power of immunocytes by improving expression of GAST.
6. The substance for improving killing power of immunocytes according to claim 1, wherein one or more of harpagide, dendrobine, coptisine hydrochloride, coptisine, norisoboldine, ginsenoside Rg3, isochlorogenic acid A, L-arginine, 3-O feruloylquinic acid, lucidone, atractyloside A, ginsenoside Rh3, cholic acid, oleuropein, paliperidone A, paliperidone B, trans-ferulate p-hydroxyphenylethanol, peonie, pseudoginsenoside RT1, anisic lactone, p-hydroxybenzoic acid, poriferic acid, oxyphyllene oxide and alpha-cyperone is used for improving killing power of immunocytes by suppressing the expression of SS 18.
7. A preparation of the substance for improving killing power of the immune cells as claimed in any one of claims 1 to 6, wherein the substance for improving killing power of the immune cells is added with pharmaceutically acceptable auxiliary materials to prepare tablets, capsules, pills, injections, slow-release agents, controlled-release agents, powders or oral liquid preparations.
8. Use of the substance for improving killing power of immune cells according to any one of claims 1 to 6, in the preparation of a medicament for treating chronic atrophic gastritis.
9. The use of the substance for increasing the lethality of immune cells according to claim 8, wherein the substance for increasing the lethality of immune cells is used for preparing a medicament for treating atrophic gastritis accompanied by immune hypofunction.
10. The use of the substance for increasing the lethality of immune cells according to claim 8, wherein the substance for increasing the lethality of immune cells is used for preparing a medicine for increasing the immunity of atrophic gastritis.
CN202011590045.0A 2020-12-29 2020-12-29 Substance for improving killing power of immune cells and preparation and application thereof Pending CN112618718A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011590045.0A CN112618718A (en) 2020-12-29 2020-12-29 Substance for improving killing power of immune cells and preparation and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011590045.0A CN112618718A (en) 2020-12-29 2020-12-29 Substance for improving killing power of immune cells and preparation and application thereof

Publications (1)

Publication Number Publication Date
CN112618718A true CN112618718A (en) 2021-04-09

Family

ID=75285961

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011590045.0A Pending CN112618718A (en) 2020-12-29 2020-12-29 Substance for improving killing power of immune cells and preparation and application thereof

Country Status (1)

Country Link
CN (1) CN112618718A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105832753A (en) * 2016-03-17 2016-08-10 云南普优生物科技有限公司 Composition containing ginsenoside Rg3 and notoginsenoside ft1
CN111067890A (en) * 2019-12-30 2020-04-28 邯郸制药股份有限公司 Substance for regulating immune function of atrophic gastritis and preparation and application thereof
CN111067908A (en) * 2019-12-30 2020-04-28 邯郸制药股份有限公司 Substance with function of improving immunity and preparation and application thereof
CN111557959A (en) * 2020-06-09 2020-08-21 张建波 Medicinal preparation for improving immunity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105832753A (en) * 2016-03-17 2016-08-10 云南普优生物科技有限公司 Composition containing ginsenoside Rg3 and notoginsenoside ft1
CN111067890A (en) * 2019-12-30 2020-04-28 邯郸制药股份有限公司 Substance for regulating immune function of atrophic gastritis and preparation and application thereof
CN111067908A (en) * 2019-12-30 2020-04-28 邯郸制药股份有限公司 Substance with function of improving immunity and preparation and application thereof
CN111557959A (en) * 2020-06-09 2020-08-21 张建波 Medicinal preparation for improving immunity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
安好义: "《中药材质量新说》", 31 January 2019, 四川科学技术出版社 *
梅全喜: "《现代中药药理与临床应用手册》", 31 October 2016, 中国中医药出版社 *
赵中振 等: "《当代药用植物典》", 30 September 2018, 上海世界图书出版社 *

Similar Documents

Publication Publication Date Title
Zhang et al. Guizhi-Shaoyao-Zhimu decoction possesses anti-arthritic effects on type II collagen-induced arthritis in rats via suppression of inflammatory reactions, inhibition of invasion & migration and induction of apoptosis in synovial fibroblasts
Zhou et al. Metformin regulates tight junction of intestinal epithelial cells via MLCK-MLC signaling pathway.
Shin et al. Anti-inflammatory effects of glycyrol isolated from Glycyrrhiza uralensis in LPS-stimulated RAW264. 7 macrophages
CN111067908A (en) Substance with function of improving immunity and preparation and application thereof
Wang et al. Blockade of TNF-α-induced NF-κB signaling pathway and anti-cancer therapeutic response of dihydrotanshinone I
Bae et al. Paeonia lactiflora root extract suppresses cancer cachexia by down-regulating muscular NF-κB signalling and muscle-specific E3 ubiquitin ligases in cancer-bearing mice
Panossian et al. Synergy assessment of fixed combinations of Herba Andrographidis and Radix Eleutherococci extracts by transcriptome-wide microarray profiling
CN108866182A (en) Application of the long-chain non-coding RNA as Alzheimer disease detection marker
CN106011303B (en) One kind serum relevant to children obesity or blood plasma miRNA marker and its application
KR20200092712A (en) Composition for improving or treating colitis and colorectal cancer comprising bioconverted herbal composition, and its preparation method
Heo et al. Anti-allergic effects of salvianolic acid A and tanshinone IIA from Salvia miltiorrhiza determined using in vivo and in vitro experiments
Cai et al. Si-Ni-San ameliorates chronic colitis by modulating type I interferons-mediated inflammation
Liu et al. Investigating the multi-target therapeutic mechanism of Guihuang formula on Chronic Prostatitis
Hong et al. The bioactive ingredients in Actinidia chinensis Planch. Inhibit liver cancer by inducing apoptosis
Mao et al. Combining transcriptomic analysis and network pharmacology to explore the mechanism by which Shaofu Zhuyu decoction improves diabetes mellitus erectile dysfunction
Lin et al. Sesamol serves as a p53 stabilizer to relieve rheumatoid arthritis progression and inhibits the growth of synovial organoids
Lin et al. 4D label-free quantitative proteomics analysis to screen potential drug targets of Jiangu Granules treatment for postmenopausal osteoporotic rats
CN113509494A (en) Application of prevotella in preparing medicine for treating cholestatic disease
Tu et al. Effect of kaempferol on hedgehog signaling pathway in rats with‐‐chronic atrophic gastritis–Based on network pharmacological screening and experimental verification
Lin et al. Study on the alleviation of Fengshi Gutong capsule on rheumatoid arthritis through integrating network pharmacology and experimental exploration
Li et al. Integrated RNA-sequencing and network pharmacology approach reveals the protection of Yiqi Huoxue formula against idiopathic pulmonary fibrosis by interfering with core transcription factors
CN112618718A (en) Substance for improving killing power of immune cells and preparation and application thereof
CN112843049A (en) Application of composition in preparing medicine for inhibiting gastric cancer cell proliferation based on regulation of CDKs and SMAD6 genes
Zhao et al. Dissecting the underlying pharmaceutical mechanism of Danggui Buxue decoction acting on idiopathic pulmonary fibrosis with network pharmacology
Liu et al. Correlation between inflammatory cytokines and liver cancer stem cell markers in DEN-induced liver cancer rats

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210409

RJ01 Rejection of invention patent application after publication